ANZCHOG Children’s Cancer Clinical Trials Repository

The ANZCHOG Children’s Cancer Clinical Trials Repository (ACCCTR) aims to provide a complete, up-to-date list of clinical trials conducted in children’s cancer centres in Australia and New Zealand.

Each trial listed contains basic information and a link to the relevant national or internal clinical trial registry such as ANZCTR, clinicaltrials.gov and EU Clinical Trials Register.

Trial eligibility is extensive and often varies depending on medical history and current health status. Your child’s oncologist and medical team are the best people to talk to about trial eligibility. They will be able to provide personalised advice based on your individual circumstances.

Study Title	Protocol ID	Condition/s	Diagnosis Stage	Location	Links	Status	Trial Open Date	Sites	Study Type	Phase	Age Eligibility	ANZCTR	International registry ID's
AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones	AALL1631	Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia	New diagnosis	NSW / QLD / WA	External Registry ≫	Open	19/04/2018	Treatment	Phase 3	1 year to 21 years at diagnosis		NCT03007147
AALL1731: A Phase 3 Trial Investigating Blinatumomab (IND# 117467& NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)	AALL1731	B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma	New diagnosis	NSW / VIC / WA / SA / NZ	External Registry ≫	Open	15/10/2019	Treatment	Phase 3	1 year to 31 Years		NCT03914625
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy	AALL1732	B Acute Lymphoblastic Leukemia B Lymphoblastic Lymphoma Central Nervous System Leukemia Mixed Phenotype Acute Leukemia Testicular Leukemia	New Diagnosis	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	28/10/2019	Treatment	Phase 3	1 Year to 24 Years		NCT03959085
AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	AAML1531	Acute Myeloid Leukemia Down Syndrome Myelodysplastic Syndrome Myeloid Leukemia Associated With Down Syndrome Myeloproliferative Neoplasm	New diagnosis	NSW / VIC / WA / NZ	External Registry ≫	Open	03/11/2015	Treatment	Phase 3	90 days to 4 years		NCT02521493
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)	AAML18P1	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	On treatment	VIC / WA	External Registry ≫	Open	15/07/2019	Treatment	Phase 2	up to 25 years		NCT03817398
ACNS1422: A phase 2 study of reduced therapy for newly diagnosed average-risk WNT-driven medulloblastoma patients	ACNS1422	Medulloblastoma	New diagnosis	NSW / WA / SA	External Registry ≫	Open		Treatment	Phase 2	3 years to 22 years at the time of enrollment		NCT02724579
ACT001-AU-002: A study to evaluate the safety and tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors	ACT001-AU-002	Advanced brain tumour Advanced solid tumour	Relapse/refractory	NSW / WA	External Registry ≫	Open	18/09/2019	Treatment	Phase 1	1 Year to 21 Years	ACTRN12618001934235
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	AGCT1531	Germ Cell Tumour	New diagnosis	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	08/05/2017	Treatment	Phase 3	Various depending on risk group & consult protocol		NCT03067181
ALLELE: Multicenter Open Label Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy	ALLELE (ATA129-EBV-302)	EBV post transplant	Refractory	NSW / VIC / WA	External Registry ≫	Open	29/12/2017	Treatment	Phase 3	no limits		NCT03394365
ALTE03N1: Key Adverse Events After Childhood Cancer	ALTE03N1	Childhood Malignant Neoplasm	Previously treated	QLD / WA / SA	External Registry ≫	Open	24/03/2004	Observational	Not applicable	up to 21 Years		NCT00082745
ALTE07C1: Neuropsychological and Social and Emotional and Behavioral Outcomes in Children with Cancer	ALTE07C1	All Tumour Types	New diagnosis Relapse/refractory	QLD / VIC / WA / SA / NZ	External Registry ≫	Open	15/09/2008	Psycho-social	Not applicable	3 Years to 21 Years		NCT00772200
ALTE11C2: Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy	ALTE11C2	Hodgkin Lymphoma in Remission Leukemia in Remission Lymphoblastic Lymphoma Osteosarcoma Recurrent Leukemia Recurrent Lymphoma Recurrent Malignant Neoplasm	Previously treated	WA	External Registry ≫	Open	05/08/2013	Late Effects	Not applicable	no limits		NCT01790152
ALTE15N2: LEAHRN (Late Effects After High-Risk Neuroblastoma) Study	ALTE15N2	Recurrent Neuroblastoma	Relapse/refractory	WA / NZ	External Registry ≫	Open	05/06/2017	Late Effects	Not applicable	5 Years to 50 Years		NCT03057626
ANBL1821: A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma	ANBL1821	Solid tumours (Neuroblastoma)	Relapse/refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	28/05/2019	Treatment	Phase 2	1 Year and older		NCT03794349
ANZUP 1302: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours	ANZUP 1302	Germ Cell Tumour	New diagnosis	QLD / NZ	External Registry ≫	Open	01/02/2014	Treatment	Phase 3	11 Years to 45 Years		NCT02582697
APEC14B1: Project: EveryChild A Registry and Eligibility Screening and Biology and Outcome Study	APEC14B1	All Paediatric Cancer Types		NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	26/10/2015	Registry	Not applicable	up to 25 years		NCT02402244
AREN03B2: Renal Tumors Classification Biology and Banking Study	AREN03B2	Renal tumours	Newly diagnosed	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	27/06/2007	Observational	Not applicable	up to 29 Years		NCT00898365
AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)	AREN1921	Anaplastic Kidney Wilms Tumor Recurrent Kidney Wilms Tumor Stage II Kidney Wilms Tumor Stage III Kidney Wilms Tumor Stage IV Kidney Wilms Tumor	New Diagnosis Relapse	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	18/09/2020	Treatment	Phase 2	up to 30 Years		NCT04322318
ARST1921: A Safety Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor Nirogacestat (PF-03084014) in Children and Adolescents With Progressive Surgically Unresectable Desmoid Tumors	ARST1921	Desmoid Fibromatosis Recurrent Desmoid Fibromatosis Unresectable Desmoid Fibromatosis	New Diagnosis Relapse	WA	External Registry ≫	Open	21/09/2020	Treatment	Phase 2	12 Months to 18 Years		NCT04195399
ASSET: Acute Lymphoblastic Leukaemia Subtype and Side-Effects from Treatment – Nationwide analysis of severe treatment-related toxicity in childhood leukaemia	ASSET	Acute Lymphoblastic Leukaemia (ALL)	Previously treated	NSW / VIC / WA / SA / NZ	External Registry ≫	Open	20/08/2015	Registry	Not applicable	up to 18 years
Developing genetically modified TCells for the treatment of paediatric solid tumours	CARTpaedST	Solid tumours	New diagnosis	NSW		Open	08/04/2018	Treatment	Phase 1	up to 18 years
CCTL019A2205B: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy	CCTL019A2205B	Patients who have received CAR-T cell therapy	Previously treated	VIC	External Registry ≫	Open	02/11/2015	Observational	Not applicable	Child, Adult, Older Adult		NCT02445222
CFZ2008: Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone and Mitoxantrone and PEG-asparaginase& and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukaemia	CFZ2008 / 20140106	Acute Lymphoblastic Leukaemia (ALL)	Relapse/refractory	NSW / QLD / VIC / WA	External Registry ≫	Open	10/09/2015	Treatment	Phase 1/2	1 Month to 21 Years		NCT02303821
CONNECT1903: A pilot and surgical study of larotrectinib for treatment of children with newly-diagnosed high-grade glioma with NTRK fusion	CONNECT1903	High Grade Glioma (HGG) Diffuse Intrinsic Pontine Glioma (DIPG)	New diagnosis	NSW / QLD / WA	External Registry ≫	Open	08/04/2021	Treatment	Pilot	up to 21 years		NCT04655404
FIREFLY: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered Recurrent or Progressive Low-Grade Glioma	DAY101-001 (FIREFLY)	Low-grade Glioma	Relapse/refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	17/03/2021	Treatment	Phase 2	6 Months to 25 Years		NCT04775485
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue	HeadStart4	Medulloblastoma Central Nervous System Embryonal Tumors	Newly diagnosed	NZ	External Registry ≫	Open	01/09/2015	Treatment	Phase 4	up to 10 Years		NCT02875314
HoTRODS: Post mortem tumour donation for Diffuse Intrinsic Pontine Glioma – developing DIPG cell cultures to test novel therapeutic strategies	HoTRODS	Diffuse Pontine Glioma Diffuse Midline Glioma High grade glioma	New Diagnosis Relapse	NSW / WA	External Registry ≫	Open	17/07/2012	Observational	Not applicable	no limits	ACTRN12612001183875
iMATRIX: A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available	iMATRIX (GO42286)	ALK Fusion-positive Solid or CNS Tumors	Relapse/refractory	NSW / VIC	External Registry ≫	Open	26/07/2021	Treatment	Phase 1/2	up to 17 Years		NCT04774718
INFORM2: Exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies	INFORM2 NivEnt	CNS Tumour Solid Tumour	Recurrent/ refractory	NSW / VIC / WA	External Registry ≫	Open	26/07/2019	Treatment	Phase 1/2	6 Years to 21 Years		NCT03838042
LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis	LCH-IV	Langerhans Cell Histiocytosis	New diagnosis	NSW / QLD / VIC / WA / NZ / TAS	External Registry ≫	Open	14/04/2014	Treatment	Phase 3	up to 18 years		NCT02205762
LOXO-RET-18036: A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours	LOXO-RET-18036	Medullary Thyroid Cancer Infantile Myofibromatosis Infantile Fibrosarcoma Papillary Thyroid Cancer Soft Tissue Sarcoma	Relapse/ refractory	NSW / VIC	External Registry ≫	Open	01/07/2019	Treatment	Phase 1/2	6 months to 21 years		NCT03899792
LOXO-TRK-15003: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	LOXO-TRK-15003	Solid Tumors Harboring NTRK Fusion	New diagnosis Relapse/ refractory	NSW / VIC / WA	External Registry ≫	Closed to Recruitment, Open	11/09/2017	Treatment	Phase 1/2	up to 21 years		NCT02637687
NB SCI Registry: Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)	NB SCI Registry	Neuroblastic Tumors		NSW / QLD / VIC / WA / SA / TAS	External Registry ≫	Open	01/04/2015	Registry	Not applicable	up to 18 Years		NCT02559804
LGG Avastin: A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma	OZM-063 (LGG Avastin)	Low Grade Glioma	New diagnosis Relapse/ refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	29/05/2018	Treatment	Phase 2	6 months to 18 years old		NCT02840409
P3505: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients	P3505	Haematological diseases	New Diagnosis Relapse/Refractory	QLD / VIC	External Registry ≫	Open	17/06/2020	Supportive Care	Phase 1	3 months to 18 years	ACTRN12620000141943
AALL1922: A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation	Ponatinib-1501 /AALL1922	Leukaemia (ALL)	Relapse/ refractory	QLD / VIC / WA	External Registry ≫	Open	21/02/2021	Treatment	Phase 1/2	1 Year to 21 Years		NCT04501614
PRISM: PRecISion Medicine for Children with Cancer	PRISM	All Paediatric Cancer Types	New Diagnosis Relapse/ Refractory	NSW / VIC / WA	External Registry ≫	Open	05/09/2017	Biology	Biology	up to 21 years		NCT03336931
R3ACT Fungal: A phase 1 trial of HLA-DR matched third party donor-derived fungus-specific cytotoxic T-lymphocytes in patients with invasive fungal disease post-allogeneic stem cell transplantation	R3ACT Fungal	Invasive Fungal Disease	Newly diagnosed Relapsed/Refractory	NSW	External Registry ≫	Open	19/08/2019	Treatment	Phase 1	1 Years to 80 Years	ACTRN12618001540202
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma	ReRAD	Recurrent or Progressive Diffuse Intrinsic Pontine Glioma	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	15/04/2017	Treatment	Phase 2	up to 17 years		NCT03126266
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma	RG_13-277 (rEECur)	Ewings sarcoma	Relapse/ refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	03/04/2018	Treatment	Phase 2/3	4 years to 50 years	ACTRN12618001825246
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	RG_17-427 (FaR-RMS)	Rhabdomyosarcoma	Relapsed/ refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	17/09/2020	Treatment	Phase 1	no limits		NCT04625907
T2017-002: A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda)	T2017-002	Acute Lymphoblastic Leukaemia (ALL)	Relapsed/ refractory	NSW / VIC	External Registry ≫	Open	12/02/2019	Treatment	Phase 1/2	1 Year to 21 Years		NCT03817320
TiNT: A phase II study of trametinib in paediatric adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas	TiNT	Solid tumours	Relapsed/ refractory	NSW / VIC / WA / SA / NZ / TAS	External Registry ≫	Open	01/03/2021	Treatment	Phase 2	3 Months to 25 Years	ACTRN12620001229965
TOTAL 17: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma	TOTAL 17	Acute Lymphoblastic Leukemia Acute Lymphoblastic Lymphoma	Newly diagnosed	VIC	External Registry ≫	Open	01/12/2021	Treatment	Phase 2/3	1 Year to 18 Years		NCT03117751
TPX-0005-07: A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations	TPX-0005-07	Solid tumours	Relapsed/ refractory	NSW / QLD / WA	External Registry ≫	Open	20/03/2020	Treatment	Phase 1/2	up to 25 years		NCT04094610
EFC16295: A Phase 3 Open-label Multicenter Study of the Safety Efficacy and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A	EFC16295	Hemophilia A	Recurrent/ refractory	QLD	External Registry ≫	Open	19/02/2021	Treatment	Phase 3	up to 12 years		NCT04759131
ACNS2021: A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor	ACNS2021	Central Nervous System Nongerminomatous Germ Cell Tumor Choriocarcinoma Embryonal Carcinoma Immature Teratoma Malignant Teratoma Mixed Germ Cell Tumor Pineal Region Germ Cell Tumor Pineal Region Immature Teratoma Pineal Region Yolk Sac Tumor Suprasellar Germ Cell Tumor	Newly diagnosed	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	04/06/2021	Treatment	Phase 2	3 Years to 30 Years		NCT04684368
DIPG: International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository	DIPG	Diffuse Intrinsic Pontine Glioma (DIPG) Diffuse Midline Glioma, H3 K27M-Mutant Diffuse Midline Glioma		NSW / QLD / WA / NZ	External Registry ≫	Open	30/06/2012	Registry	Not applicable	Child, Adult, Older Adult		NCT03101813
PPB DICER: International Pleuropulmonary Blastoma Registry for PPB DICER1 and Associated Conditions	PPB DICER	Pleuropulmonary Blastoma Wilms Tumor Pineoblastoma Neuroblastoma Embryonal Rhabdomyosarcoma		NSW / WA	External Registry ≫	Open	06/12/2015	Registry	Not applicable	Child, Adult, Older Adult		NCT03382158
Bu4Day-PK-2016: Analysis of Total Busulfan Exposure for Once Daily Intravenous Dosing in Paediatric Haematopoietic Stem Cell Transplantation- An ANZCHOG Pilot Study	Bu4Day-PK-2016	Haematopoietic Stem Cell Transplant	Newly diagnosed Relapsed/refractory	NSW / QLD / WA	External Registry ≫	Open	29/05/2017	Observational	Pilot	up to 18 years	ACTRN12617000227392
ACOR: Australian Cardio-Oncology Registry	ACOR	All paediatric cancer types	Newly diagnosed	NSW / VIC / WA / SA / TAS		Open	01/09/2018	Registry	Not applicable	up t 35 Years
PREDICT: Assessment of the Utility of Family-based (Trio) Whole-genome Sequencing for Cancer Predisposition Testing in Sequential Newly Diagnosed Paediatric and Adolescent Cancer Patients	PREDICT	Neoplastic Syndromes, Hereditary Cancer Genetic Predisposition to Disease	Newly diagnosed	NSW	External Registry ≫	Open	08/03/2021	Observational	Not applicable	up to 21 years		NCT04903782
ALL Registry: Patient Responses to Treatments: An Acute Leukaemia Registry; Minimal Residual Disease testing; Molecular Subtyping and Biobanking for Future Research	Acute Leukaemia Registry	Leukaemia		NSW / QLD / VIC / WA / TAS		Open	01/04/2019	Registry	Not applicable	Child, Adult, Older Adult
BLU-285-3101: A Phase 1/2 Single-arm Study to Evaluate the Safety Pharmacokinetics and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling	BLU-285-3101	Solid tumours CNS Tumours	Relapse/refractory	NSW / VIC	External Registry ≫	Open	14/10/2022	Treatment	Phase 1/2	2 Years to 17 Years		NCT04773782
ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma	ANHL1931	Primary Mediastinal Large B-Cell Lymphoma	Newly Diagnosed	NSW / QLD / VIC / WA	External Registry ≫	Open	07/06/2021	Treatment	Phase 3	2 Years and older		NCT04759586
ARST2031: A Randomized Phase 3 Trial of Vinorelbine Dactinomycin and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)	ARST2031	Rhabdomyosarcoma	Newly diagnosed	NSW / VIC / WA	External Registry ≫	Open	12/09/2023	Treatment	Phase 3	up to 50 Years		NCT04994132
MetMED: Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric medulloblastoma patients	MetMED	Medulloblastoma	Previously treated	NSW / VIC / WA	External Registry ≫	Open	28/09/2022	Treatment	Phase 3	7 years to 17 years	ACTRN12622000045718
M20-429: A Single Arm Open-Label Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms	M20-429	Non-Hodgkin Lymphoma	Relapsed/refractory	NSW / VIC / WA	External Registry ≫	Open	29/09/2022	Treatment	Phase 1/2	1 Year to 21 Year5		NCT05206357
PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression	PNOC022	Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Diffuse Midline Glioma, H3 K27M-Mutant Recurrent WHO Grade III Glioma WHO Grade III Glioma	Newly diagnosed Relapsed/Refractory	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	18/08/2022	Treatment	Phase 1/2	2 Years to 39 Years		NCT05009992
CA224-069: A Phase 1/2 Study of the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma	CA224-069	Non-Hodgkin Lymphoma	Relapsed/Refractory	NSW / QLD / WA	External Registry ≫	Open	01/11/2022	Treatment	Phase 1/2	up to 30 Years		NCT05255601
CONNECT2108: Phase 2 Study of the MEK inhibitor MEKTOVI® (binimetinib) for the treatment of Pediatric Adamantinomatous Craniopharyngioma	CONNECT2108	Adamantinomatous Craniopharyngioma	Relapsed/refractory	NSW / QLD / WA	External Registry ≫	Open	08/05/2023	Treatment	Phase 2	1 Year to 25 Years		NCT05286788
CO43810: A phase i/ii open-label single-arm two-part trial to evaluate safety tolerability pharmacokinetics and anti-tumor activity of glofitamab in combination with chemoimmunotherapy in pediatric and young adult participants with relapsed/refractory mature b-cell non-hodgkin lymphoma	CO43810	Mature B-Cell Non-Hodgkin Lymphoma	Relapsed/refractory	QLD / WA	External Registry ≫	Open	16/11/2022	Treatment	Phase 1/2	6 Months to 30 Years		NCT05533775
D0816C00025: A Phase 1 Open-label Parallel Group Study to Investigate Olaparib Safety andTolerability Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours	D0816C00025	Solid Tumours	Relapsed/refractory	NSW / WA	External Registry ≫	Open	01/11/2022	Treatment	Phase 1	0 Years to 18 Years		NCT04236414
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Pediatric Adamantinomatous Craniopharyngioma	CONNECT1905	Adamantinomatous Craniopharyngioma	Relapsed/refractory	NSW / QLD / WA	External Registry ≫	Open	19/12/2022	Treatment	Phase 2	1 Year to 25 Years		NCT05233397
ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)	ACNS1821	Anaplastic Astrocytoma Anaplastic Astrocytoma, Not Otherwise Specified Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Glioblastoma Glioblastoma, Not Otherwise Specified Malignant Glioma	Newly diagnosed	NSW / QLD / VIC / NZ	External Registry ≫	Open	05/05/2022	Treatment	Phase 1/2	12 Months to 21 Years		NCT05099003
APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations	APEC1621F	All paediatric cancer types	Relapsed/refractory	WA	External Registry ≫	Open	17/04/2018	Treatment	Phase 2	12 Months to 21 Years		NCT03213652
ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma	ARET2121	Bilateral Retinoblastoma Childhood Intraocular Retinoblastoma Group D Retinoblastoma Stage I Retinoblastoma Unilateral Retinoblastoma	Newly diagnosed	WA	External Registry ≫	Open		Treatment	Phase 2	up to 18 Years		NCT05504291
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	AOST2031	Metastatic Malignant Neoplasm in the Lung Metastatic Osteosarcoma Osteosarcoma	Newly diagnosed	NSW / VIC / WA / NZ	External Registry ≫	Open	13/01/2023	Treatment	Phase 3	up to 50 Years		NCT05235165
ARST2032: A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma	ARST2032	Embryonal Rhabdomyosarcoma Fusion-Negative Alveolar Rhabdomyosarcoma Spindle Cell/Sclerosing Rhabdomyosarcoma	Newly diagnosed	NSW / WA / NZ	External Registry ≫	Open	09/12/2022	Treatment	Phase 3	up to 21 years		NCT05304585
ASCT2031: A Multi-Center Phase 3 Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children Adolescents and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)	ASCT2031	Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome	Newly diagnosed	NSW	External Registry ≫	Open	12/12/2023	Treatment	Phase 3	6 Months to 22 Years		NCT05457556
Firefly-2: A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy	Firefly-2	Low-Grade Glioma	Newly diagnosed	NSW / QLD / VIC / WA / SA / NZ	External Registry ≫	Open	19/05/2023	Treatment	Phase 3	up to 25 Years		NCT05566795
APAL2020D: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML	APAL2020D	Acute myeloid leukemia	Relapsed/refractory	QLD / VIC / WA / NZ	External Registry ≫	Open	01/10/2022	Treatment	Phase 3	29 Days to 21 Years		NCT05183035
TAK-620-2004: A Phase 3 Open-label Single-arm Repeated-dose Study to Evaluate the Safety and Tolerability Pharmacokinetics and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)	TAK-620-2004	Cytomegalovirus (CMV)	Previously treated	NSW / QLD / WA	External Registry ≫	Open	29/05/2024	Treatment	Phase 3	up to 17 Years		NCT05319353
APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias	APAL2020SC	Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Post Cytotoxic Therapy Juvenile Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Myelodysplastic Syndrome Post Cytotoxic Therapy Myeloid Leukemia Associated With Down Syndrome	Relapsed/refractory	NSW / QLD / VIC / WA / NZ	External Registry ≫	Open	30/11/2021	Observational	Not applicable	up to 22 Years		NCT04726241
ZERO2: Precision Medicine for Every Child With Cancer	ZERO2	All paediatric cancer types	Newly diagnosed Relapsed/Refractory	NSW / QLD / VIC / WA / SA / NZ / TAS	External Registry ≫	Open	16/12/2022	Observational	Not applicable	0 Years to 25 Years		NCT05504772
LTS16294: A Phase 3 Open-label Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Patients With Severe Hemophilia A	LTS16294	Hemophilia A	Previously treated	NSW / QLD / WA	External Registry ≫	Open	23/02/2022	Treatment	Phase 3	Child, Adult, Older Adult		NCT04644575
HR NBL2: High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	HR NBL2	Neuroblastoma	Newly diagnosed	NSW / VIC	External Registry ≫	Open	31/03/2023	Treatment	Phase 3	up to 20 years		NCT04221035
CAMPFIRE: A Randomized Open-Label Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing’s Sarcoma	CAMPFIRE- J1S-MC-JP04	Ewing Sarcoma Neoplasm Metastasis	Relapsed/refractory	NSW / VIC	External Registry ≫	Open	10/09/2022	Treatment	Phase 2	1 Year to 39 Years		NCT05440786
PEPN2121: A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	PEPN2121	Atypical Teratoid/Rhabdoid Tumor Epithelioid Sarcoma Kidney Medullary Carcinoma Malignant Solid Neoplasm Poorly Differentiated Chordoma Recurrent Atypical Teratoid/Rhabdoid Tumor Recurrent Chordoma Recurrent Epithelioid Sarcoma Recurrent Kidney Medullary Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Rhabdoid Tumor Refractory Atypical Teratoid/Rhabdoid Tumor Refractory Chordoma Refractory Epithelioid Sarcoma Refractory Kidney Medullary Carcinoma Refractory Malignant Solid Neoplasm Refractory Rhabdoid Tumor Rhabdoid Tumor	Newly diagnosed Relapsed/Refractory	NSW / QLD	External Registry ≫	Open	16/08/2024	Treatment	Phase 1/2	12 Months and older		NCT05286801
PEPN22P1: A Pharmacokinetic Study of Vincristine in Infants Dosed According to BSA Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods	PEPN22P1	Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm	Newly diagnosed Relapsed/Refractory	QLD	External Registry ≫	Open	22/06/2023	Treatment	Pilot	up to 12 Years		NCT05359237
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma	AOST2032	High Grade Osteosarcoma Localized Osteosarcoma Metastatic Osteosarcoma Secondary Osteosarcoma	Newly diagnosed	NSW / VIC / NZ	External Registry ≫	Open		Treatment	Phase 2/3	up to 40 Years		NCT05691478
T2020-006: A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies	T2020-006	Acute lymphoblastic leukemia Acute myeloid leukemia Myelodysplastic syndrome Mixed phenotype acute leukemia Acute undifferentiated leukemia Blastic plasmacytoid dendritic cell neoplasm Hodgkin lymphoma Non-Hodgkin lymphoma	Relapsed/refractory	NSW / VIC	External Registry ≫	Open	11/11/2022	Treatment	Phase 1	1 Year to 21 Years		NCT05476770
The CLOCK Trial: Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)	The CLOCK Trial	All paediatric cancers Central vascular access device (CVAD) related adverse events		NSW / QLD / VIC	External Registry ≫	Open	10/07/2023	Observational	Not applicable	0 Years to 18 Years	ACTRN12622000499785
Interfant21: International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia	Interfant21	B- precursor acute lymphoblastic leukemia (ALL) B- cell mixed phenotype acute leukemia (MPAL)	Newly diagnosed	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	30/04/2024	Treatment	Phase 3	up to 1 Year		NCT05327894
ONC201-108: ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized Double-Blind Placebo-Controlled Multicenter Study	ONC201-108	H3 K27M-mutant diffuse glioma	Newly diagnosed	NSW / WA / TAS	External Registry ≫	Open		Treatment	Phase 3	Child, Adult, Older Adult		NCT05580562
DEFLEXIFOL (DART): Phase I/II Trial of Deflexifol for Refractory/Recurrent Paediatric Ependymoma	DEFLEXIFOL (DART)	Ependymoma	Relapsed/refractory	NSW / QLD / VIC / WA / SA	External Registry ≫	Open	28/08/2023	Treatment	Phase 1/2	12 Months to 21 Years	ACTRN12623000104651
AAML1831: A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations	AAML1831	Acute Myeloid Leukemia	Newly diagnosed	QLD	External Registry ≫	Open	21/07/2020	Treatment	Phase 3	up to 21 Years		NCT04293562
CBYL719P12201: A Two-stage Double-blind Randomized Placebo-controlled Study to Assess the Efficacy Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Associated Lymphatic Malformations With a PIK3CA Mutation.	CBYL719P12201	Lymphatic Malformations	Newly diagnosed Relapsed/Refractory	QLD	External Registry ≫	Open	24/11/2023	Treatment	Phase 1/2	2 Years and older		NCT05948943 /
P305: Phase I clinical trial of adoptive transfer of multi-virus-specific T cells into TCRaß+/CD19+-depleted haploidentical HSCT recipients	P305	Haematological diseases	New Diagnosis Relapse/Refractory	VIC	External Registry ≫	Open	17/06/2020	Supportive Care	Phase 1	3 months to 18 years	ACTRN12620000141943
CLEE011Q12101: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors	CLEE011Q12101	Neuroblastoma Medulloblastoma High-grade glioma Malignant rhabdoid tumor Rhabdomyosarcoma	Relapse/refractory	NSW	External Registry ≫	Open	27/12/2022	Interventional	Phase 1/2	12 months to 21 years		NCT05429502 /
REGO-EWING: Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma	REGO-EWING	Multimetastatic Ewing Sarcoma	Newly diagnosed	QLD / VIC / WA	External Registry ≫	Open	27/03/2023	Treatment	Phase 1	2 Years to 50 Years		NCT05830084
INTER-EWING-1: INTERnational scientific program in clinical research to improve outcomes of newly diagnosed EWING sarcoma	RG_21-151 (INTER-EWING-1)	Ewing Sarcoma	Newly Diagnosed	VIC / WA / NZ	External Registry ≫	Open	21/06/2024	Treatment	Phase 3	≥2 years	ACTRN12624000532505	ISRCTN17938906
OPTIMISE: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	OPTIMISE	Bone Cancers Brain and other CNS Tumours Germ Cell Tumours Hodgkin Lymphoma Kidney (Renal) Tumours Leukaemia Liver tumours Neuroblastoma Non-Hodgkin Lymphoma Retinoblastoma Soft Tissue Sarcomas Other	Relapsed/Recurrent	NSW / QLD / VIC / WA	External Registry ≫	Open	01/03/2024	Treatment	Phase 1/2	0 - 21 years	NCT06208657
VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas	VICTORY	Brain and other Central Nervous System (CNS) Tumours Low Grade Glioma	Relapsed/Recurrent	WA	External Registry ≫	Open	23/12/2024	Treatment	Pilot	Up to 25 Years		NCT06381570

Study Title

Protocol ID

Condition/s

Diagnosis Stage

Location

Links

Status

Trial Open Date

Trial Close Date

Sites

Study Type

Phase

Age Eligibility

ANZCTR

International registry ID's

AALL1631: International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

AALL1631

Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
T Acute Lymphoblastic Leukemia

New diagnosis

NSW / QLD / WA

Filter by

Join our newsletter